RUNX1T1 and neuroblastoma: In particular, BPPB demonstrated very potent antiproliferative effects against neuroblastoma (NB) cells, including both sensitive HTLA-230 NB cells (IC50 = 0.2 μM) and multidrug-resistant HTLA-ER NB cells (IC50 = 1.1 μM), which have developed tolerance to ETO (IC50 = 592 μM), DOX, carboplatin, cisplatin, vincristine, and other clinically used drugs.